Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • ENT
  • ENT Perspective
  • Practice Patterns...

Practice Patterns About Management of Allergic Rhinitis: Indian HCP KAP Experience in 2024 and Preference of Fexofenadine and Montelukast

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2024-10-29T10:00:00+05:30  |  Updated On 29 Oct 2024 4:35 PM IST
Practice Patterns About Management of Allergic Rhinitis: Indian HCP KAP Experience in 2024 and Preference of Fexofenadine and Montelukast
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Allergic Rhinitis (AR) is the most common immune-mediated inflammatory condition affecting the nasal mucosa (1) triggered by the production of IgE antibodies on exposure to an allergen leading to nasal passage inflammation (1,2). It affects 40% of the global population and 22% of adolescents in India. About 9.8% of the symptoms begin in childhood and adolescence. Urbanization, environmental changes, geography, seasonal variations, lifestyle changes, and pollution are some risk factors that precipitate AR (2).

Management of Allergic Rhinitis (AR) – Overview:

Allergic Rhinitis (AR) management aims to improve the affected individuals' symptoms and quality of life. Allergen avoidance, pharmacotherapy, and immunotherapy are the management strategies for AR. Allergic Rhinitis and its Impact on Asthma and British Society for Allergy and Clinical Immunology guidelines have put forward general clinical management guidelines that include allergen avoidance and oral or intranasal antihistamines or leukotriene receptor antagonists, oral/nasal decongestants ± nasal irrigation, intranasal corticosteroids, ipratropium, and immunotherapy (3).

Indian Medical Association has put forward management guidelines, including allergen avoidance and other medications like antihistamines and leukotriene receptor antagonists (LTRAs). The guidelines also recommended using LTRAs in combination with antihistamines due to their synergistic effect in improving nasal symptoms in the first 24 hours to 6 weeks (4). Among the various medications used, antihistamines, leukotriene receptor antagonists, and intranasal corticosteroids are the commonly used drugs for AR(5).

Combining Antihistamines plus Leukotriene Receptor Antagonists (LTRA) for AR: Synergy for Optimal Clinical Symptom Resolution:

The combination of antihistamines or LTRA is beneficial for individuals who cannot get relief from monotherapy (6). The anti-inflammatory effect of fexofenadine and the bronchodilator effect of montelukast can effectively reduce nasal symptoms in AR (7). Antihistamines improve daytime nasal symptoms like stuffy, runny, itchy nose and sneezing. LTRAs are effective for nighttime symptoms like nasal congestion, sleeping difficulty, and awakenings. Hence, combining antihistamines and LTRA can improve daytime and nighttime symptoms (8). Among the various types of AR, the combination can be more advantageous in perennial AR by reducing the composite nasal and ocular symptoms (9).

Fexofenadine and Montelukast Combination in Allergic Rhinitis:

Fexofenadine is a second-generation antihistamine approved by the U.S. Food and Drug Administration (FDA) that selectively antagonizes H1 receptors with reduced affinity for cholinergic and α-adrenergic receptors and minimal crossing of the blood-brain barrier (BBB), which makes it one of the least sedating antihistamines used to treat AR (10). Montelukast is an orally active, highly selective cysteinyl LTRA of leukotriene D4 that is well tolerated, mostly plasma protein bound, and has minimal distribution across the blood-brain barrier (11).

Fexofenadine and Montelukast - Review of Clinical Literature:

Montelukast + fexofenadine is more effective than Montelukast + levocetirizine:

A prospective, randomized, double-blind, parallel, active-controlled, comparative 4-week trial conducted on AR patients aged 18-65 years revealed that the Montelukast-fexofenadine (10mg &120mg respectively) combination was more effective than the montelukast-levocetirizine (10mg & 5mg) group in reducing the total nasal symptom score (TNSS).

The study found that the patients' TNSS scores significantly reduced from baseline to 4 weeks based on the intensity of nasal symptoms. Symptoms like rhinorrhoea, nasal itching, nasal obstruction, and sneezing were measured using a 4-point Likert scale from 0 to 3. Thus, the study concluded that Montelukast + fexofenadine was more effective than Montelukast + levocetirizine (7).

Take Home Messages:

  • AR is a common immune-mediated inflammatory condition affecting 40% of the population globally triggered by various allergens
  • Allergen avoidance, pharmacotherapy, and immunotherapy are the management strategies for AR.
  • Fexofenadine is a second-generation antihistamine, while Montelukast is an LTRA. Both are well-tolerated. Compared to monotherapy, the combination can improve daytime and nighttime symptoms.
  • A combination of montelukast and fexofenadine is more effective in reducing total nasal symptom score, with better outcomes in terms of symptom relief and quality of life.

References:

1. Gupte V, Thakur G, Upadhyaya A, Jain S, Bhargava S. A Perception-Based Survey on Practice Patterns About the Diagnosis and Management of Allergic Rhinitis in India. Cureus. 2024 Feb 27;

2‌. S M, M KK. Prescription trends and patterns for allergic rhinitis treatment in clinical practice. International Journal of Otolaryngology Sciences. 2024 Jan 1;6(1):01–5.

‌3. Siddiqui Z, Walker A, Pirwani M, Tahiri M, Syed I. Allergic rhinitis: diagnosis and management. British Journal of Hospital Medicine. 2022 Feb 2;83(2):1–9.

4. Indian Medical Association (IMA). Allergic Disorder: Simplify Allergic Management in India. Retrieved on 16th October 2024. IMAHQ_Allergy Booklet_2.pdf.

5. Abdullah B, Abdul Latiff AH, Manuel AM, Mohamed Jamli F, Dalip Singh HS, Ismail IH, Jahendran J, Saniasiaya J, Keen Woo KC, Khoo PC, Singh K, Mohammad N, Mohamad S, Husain S, Mösges R. Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology. J Asthma Allergy. 2022 Aug 2;15:983-1003. doi: 10.2147/JAA.S374346. PMID: 35942430; PMCID: PMC9356736.

6. Maladkar M, Patil S, S Kamble. Role of Antihistamine and Leukotriene Receptor Antagonist in Allergic Rhinitis Management: Newer Perspectives. The Indian Practitioner [Internet]. 75(6):28–34. Available from: https://www.researchgate.net/profile/Manish-Maladkar/publication/361814914_Role_of_Antihistamine_and_Leukotriene_Receptor_Antagonist_in_Allergic_Rhinitis_Management_Newer_Perspectives/links/62c6bc53959dc1752ff7c38a/Role-of-Antihistamine-and-Leukotriene-Receptor-Antagonist-in-Allergic-Rhinitis-Management-Newer-Perspectives.pdf

7. Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. PMID: 28066101; PMCID: PMC5155464.

8. Feng Y, Meng YP, Dong YY, Qiu CY, Cheng L. Management of allergic rhinitis with leukotriene receptor antagonists versus selective H1-antihistamines: a meta-analysis of current evidence. Allergy Asthma Clin Immunol. 2021 Jun 29;17(1):62. doi: 10.1186/s13223-021-00564-z. PMID: 34187561; PMCID: PMC8243504.

9. Liu G, Zhou X, Chen J, Liu F. Oral Antihistamines Alone vs in Combination with Leukotriene Receptor Antagonists for Allergic Rhinitis: A Meta-analysis. Otolaryngology–Head and Neck Surgery. 2018 Jan 16;158(3):450–8.

10. Craun KL, Patel P, Schury MP. Fexofenadine. [Updated 2024 Feb 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556104/.

11. Lagos JA, Marshall GD. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag. 2007 Jun;3(2):327-32. doi: 10.2147/tcrm.2007.3.2.327. PMID: 18360641; PMCID: PMC1936314.

allergic rhinitisarallergensallergic rhinitis indiafexofendinemontelukastfexofenadine and montelukastltraantihistamineallegra mallegraallergic rhinitis manaagementallergic rhinitis management indiaindian guideline on arindian medical associationima allergic rhinitis
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

Relevance of Pioglitazone in Indian T2DM Care Continuum

Relevance of Pioglitazone in Indian T2DM Care Continuum

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

View All

Journal Club Today

Study Reveals Why Your Immune System Works Better in Daylight

Study Reveals Why Your Immune System Works Better in Daylight

View All

Health News Today

Health Bulletin 29/May/2025

Health Bulletin 29/May/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok